Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;78(1):150-152.
doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Andrew L Mammen #  1 , Arun Rajan #  2 , Katherine Pak  3 , Tanya Lehky  4 , Livia Casciola-Rosen  5 , Renee N Donahue  6 , Lauren M Lepone  6 , Anastasia Zekeridou  7 , Sean J Pittock  7 , Raffit Hassan  2 , Jeffrey Schlom  6 , James L Gulley  6   8
Affiliations

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Andrew L Mammen et al. Ann Rheum Dis. 2019 Jan.
No abstract available

Keywords: B cells; autoantibodies; autoimmune diseases; autoimmunity; polymyositis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1.
Figure 1.
Immune cell subsets in thymoma patients prior to treatment with avelumab. Flow cytometry was performed on peripheral blood mononuclear cells prior to avelumab treatment. Cell types were defined as follows: regulatory T cells are CD4+ CD25+ FoxP3+ CD127−, natural killer cells are CD56+ CD3−, and myeloid derived suppressor cells are CD11b+ HLA-DRlow/− CD33+. The median and interquartile ranges are indicated by long and short horizontal bars, respectively. The patient without myositis who developed autoimmune enteritis is noted with an open square.
See this image and copyright information in PMC

References

    1. Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 2018. doi: 10.1002/cncr.31293 [published Online First: 2018/02/23] - DOI - PMC - PubMed
    1. Heery CR, O'Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017;18(5):587–98. doi: 10.1016/S1470-2045(17)30239-5 - DOI - PMC - PubMed
    1. Bernard C, Frih H, Pasquet F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 2016;15(1):82–92. doi: 10.1016/j.autrev.2015.09.005 [published Online First: 2015/09/27] - DOI - PubMed
    1. Chen JH, Lee KY, Hu CJ, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Medicine (Baltimore) 2017;96(50):e9262. doi: 10.1097/MD.0000000000009262 [published Online First: 2018/02/03] - DOI - PMC - PubMed
    1. Montella L, Masci AM, Merkabaoui G, et al. B-cell lymphopenia and hypogammaglobulinemia in thymoma patients. Ann Hematol 2003;82(6):343–7. doi: 10.1007/s00277-003-0635-z [published Online First: 2003/04/26] - DOI - PubMed

Publication types

MeSH terms